Maximum of 20 days of oral dosing in the first 2 years with no further treatment required in the next 2 years1
Click here to view MAVENCLAD® indications and contraindications
The content on this site is intended for Healthcare Professionals only and contains educational and promotional material.
Important notice: By entering this site, you are confirming that you are a healthcare professional in the UK or Ireland.
Yes, I am a UK or ROI Healthcare ProfessionalBy logging in to our website you will have full access to its content, including Healthcare Professional resources. Click here to register or login below.
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk. In the Republic of Ireland information can be found at http://www.hpra.ie. Adverse events should also be reported to Merck Serono Limited - Tel: +44(0)20 8818 7373 or email: medinfo.uk@merckgroup.com.
You may request sponsorship to attend a Merck organised meeting. Merck is committed to supporting the professional development and clinical education of healthcare professionals in MS.
Your local storage for MerckNeurology.co.uk has been cleared. If you continue to use this website we may continue utilise your browsers local storage.